Latest Conference Articles

A discussion with Kevin Cowart, PharmD, MPH, BCACP, FCCP, BCPS, assistant professor at the University of South Florida Taneja College of Pharmacy.

John Bucheit, PharmD, discussed lipid-lowering medications and how nonstatins can be beneficial for cardiovascular health.

A discussion with Brittany Norton, PharmD, director of ambulatory care at Sutter Health.

Navigating Cannabis use requires more than just an understanding of the endocannabinoid system.

Researchers explored the disease activity of patients with axial spondylarthritis after various modifications to their diets.

Researchers aimed to address the associations between gout and ischemic events, specifically ischemic colitis.

A number of new, nonopioid osteoarthritis treatment options are either available for patients or in the development pipeline.

PROMIS scores demonstrated the disparities between reported pain and mental health outcomes.

Despite an interest in services, a majority of women do not have these critical conversations with their health care providers.

NSAIDS are typically the first line of treatment for axial spondyloarthritis.

Chronic pain is more prevalent—and more severe—in veterans compared with the general US population.

Research presented at American Heart Association’s 2024 Scientific Sessions examined the SGLT inhibitor’s effect on systolic blood pressure.

Investigators evaluated the role that cannabis plays in pain management in different populations with rheumatic diseases.

Premenstrual Dysphoric Disorder is considered a psychiatric disorder and is associated with moderate to severe physical, affective, and behavioral symptoms.

“[O]ur data do not support the hypothesis that early COVID resulted in more significant structural or electrical cardiac remodeling that would increase the likelihood of atrial fibrillation progression,” the authors said.

The Mediterranean diet is largely considered one of the healthiest diets.

Two posted presented at the American Heart Association’s 2024 Scientific Sessions explored empagliflozin among patients with type 2 diabetes and cardiovascular risk.

Three research posters presented at the American Heart Association’s 2024 Scientific Sessions looked into the use of SGLT-2 inhibitors in patients with type 2 diabetes and cardiovascular complications.

Patients with type 2 diabetes who had eating problems and higher levels of diabetes distress had worse time-in-range.

A PDUFA date for acoramidis has been set for November 29, 2024.

A conversation with Trent Thiede, PharmD, MBA, president of PAAS National, at NCPA 2024.

Pharmacy experts from AON Pharmacy in Florida discussed the Inflation Reduction Act and how it affects reimbursement for Medicare Part D drugs.

A conversation with AJ Loiacono, co-founder and CEO of Capital RX, at NCPA 2024.

Selina Coleman, JD, Partner in Life Sciences Health Industry Group at Reed Smith LLP, discussed recent developments in Supreme Court decisions impacting pharmacy operations.

An FDA representative gave a presentation on her organization’s recent updates regarding drug supply chain rules and regulations.

Pharmacy law experts detailed the Drug Supply Chain Security Act, highlighting the role each entity within the supply chain plays in ensuring the safety and authenticity of US prescription drugs.

FDA experts gathered to discuss the DEA’s rescheduling of marijuana and how it will impact the pharmaceutical supply chain.

Stephen Schondelmeyer, PharmD, PhD, FAPhA, gave a presentation on US drug shortages and their global implications.